The what? Revlon has reported Q4 net sales of US$615.2 million, down from US$626.6 million in the previous year, a 1.8 percent drop.
The details Reported operating income reached US$67.3 million in the fourth quarter of 2021, compared to US$28.4 million during the prior-year period, an improvement of US$38.9 million.
Looking at segments, Revlon net sales reached US$206.1 million – a 0.2 percent increase YOY. Profit reached US$41.5 million, an 8 percent YOY increase.
Elizabeth Arden net sales were down 4.7 percent to US$172.6 million, the Portfolio segment grew 8.2 percent to US$111.7 million, while the fragrance segment net sales decreased to $124.8 million, a drop of 8.7 percent.
FY2021 net sales saw a 9.2 percent increase to US$2,078.7 million, with reported operating income reaching US$103.2 million in 2021, compared to $226.3 million of loss during the prior year.
The why? Debra Perelman, Revlon’s President and Chief Executive Officer, said: “Consumer demand for our brands remained strong in the 4th Quarter, as evidenced by Revlon Color Cosmetics’ 30% year-over-year retail sales growth in the important US Mass channel.
“While we saw strong consumer demand, we also continued to experience industry-wide supply chain challenges, which impacted our ability to fully meet customer orders to support this consumption. Starting in the 3rd quarter, our business has been impacted by increased prices on key ingredients and components, logistics challenges across all modes of transportation delaying receipt of goods, and persistent labor shortages.”
Aesthetic injectable companies refer to businesses or companies that specialize in manufacturing, distributing, or providing aesthetic injectable products and services. These companies focus on developing and supplying injectable substances used for cosmetic purposes, typically administered by qualified medical professionals. Aesthetic injectable companies play a crucial role in the field of aesthetic medicine and cosmetic dermatology by offering a variety of injectable products designed to enhance facial features, reduce wrinkles, and improve overall skin appearance.
Key aspects of aesthetic injectable companies include:
-
Product Development: These companies research, develop, and manufacture aesthetic injectables such as dermal fillers, botulinum toxins (e.g., Botox), collagen stimulators, and other specialized formulations. They often innovate new products to meet evolving market demands and technological advancements.
-
Distribution and Sales: Aesthetic injectable companies distribute their products through authorized channels, including healthcare providers, medical spas, and aesthetic clinics. They may also sell directly to licensed professionals who administer these treatments.
-
Regulatory Compliance: Due to the medical nature of their products, aesthetic injectable companies adhere to strict regulatory guidelines and obtain necessary approvals from health authorities (e.g., FDA in the United States) to ensure safety, efficacy, and quality standards.
-
Training and Support: Many companies provide training and educational support to healthcare professionals on the proper use, administration techniques, and safety protocols associated with their injectable products. This ensures that practitioners can deliver treatments effectively and safely.
-
Customer Support: Aesthetic injectable companies offer customer support services to healthcare providers and consumers, addressing inquiries, providing product information, and assisting with product usage and troubleshooting.
